U.S. markets open in 4 hours 14 minutes
  • S&P Futures

    3,706.00
    +36.00 (+0.98%)
     
  • Dow Futures

    29,571.00
    +228.00 (+0.78%)
     
  • Nasdaq Futures

    11,443.75
    +127.50 (+1.13%)
     
  • Russell 2000 Futures

    1,682.20
    +19.70 (+1.18%)
     
  • Crude Oil

    77.60
    +0.89 (+1.16%)
     
  • Gold

    1,642.60
    +9.20 (+0.56%)
     
  • Silver

    18.59
    +0.11 (+0.60%)
     
  • EUR/USD

    0.9627
    +0.0016 (+0.16%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    31.08
    +1.16 (+3.88%)
     
  • GBP/USD

    1.0787
    +0.0103 (+0.97%)
     
  • USD/JPY

    144.4050
    -0.2750 (-0.19%)
     
  • BTC-USD

    20,129.13
    +901.85 (+4.69%)
     
  • CMC Crypto 200

    459.55
    +26.45 (+6.11%)
     
  • FTSE 100

    7,009.72
    -11.23 (-0.16%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

What's Going On With Corvus Pharmaceuticals Stock Today?

·1 min read

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for patients with unresectable, stage 3 non-small cell lung cancer.

The average session volume over a 100-day period is about 300,000. Friday's session volume was approaching 120 million at publication time.

AZN News: AstraZeneca announced that "the COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival and objective response rate compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer who had not progressed after concurrent chemoradiation therapy."

The results may be positively impacting Corvus Pharmaceuticals, which has a CD73 asset in its pipeline.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system.

CRVS Price Action: Corvus Pharmaceuticals has traded as high as $5.74 and as low as $1.86 over a 52-week period.

The stock was up 72.60% at $3.90 at time of publication.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.